Jump Financial LLC Acquires 20,559 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

Jump Financial LLC grew its holdings in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 778.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,200 shares of the company's stock after buying an additional 20,559 shares during the quarter. Jump Financial LLC's holdings in Dr. Reddy's Laboratories were worth $366,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in RDY. Geode Capital Management LLC grew its holdings in shares of Dr. Reddy's Laboratories by 109.3% during the third quarter. Geode Capital Management LLC now owns 13,254 shares of the company's stock valued at $1,053,000 after buying an additional 6,920 shares during the last quarter. Virtu Financial LLC purchased a new position in Dr. Reddy's Laboratories during the third quarter worth about $276,000. World Investment Advisors LLC purchased a new position in Dr. Reddy's Laboratories during the third quarter worth about $3,459,000. B. Riley Wealth Advisors Inc. purchased a new position in Dr. Reddy's Laboratories during the third quarter worth about $490,000. Finally, Confluence Investment Management LLC boosted its holdings in Dr. Reddy's Laboratories by 400.0% during the fourth quarter. Confluence Investment Management LLC now owns 18,290 shares of the company's stock worth $289,000 after purchasing an additional 14,632 shares during the last quarter. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Dr. Reddy's Laboratories Stock Up 1.2 %

Dr. Reddy's Laboratories stock traded up $0.16 during midday trading on Monday, hitting $13.95. 1,320,112 shares of the stock were exchanged, compared to its average volume of 1,468,885. The stock has a market capitalization of $11.65 billion, a price-to-earnings ratio of 22.21 and a beta of 0.51. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. Dr. Reddy's Laboratories Limited has a 52-week low of $12.26 and a 52-week high of $16.89. The business's 50-day moving average price is $13.18 and its 200-day moving average price is $14.19.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, research analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.